DDInter905 DDInter1658
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Idelalisib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Idelalisib {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Idelalisib may lead to a major life threatening interaction when taken with Vinorelbine